Discover
UTHR
United Therapeutics Corporation
547.15
1 x 549.35
1 x 541.72
bid
ask
+
5.32
0.98%
1 @ 04:16 AM
547.15 +0.00 (0.00%)
| Ytd | 12.29% | |
| 1y | 85.34% |
536.93
day range
549.66
272.12
52 week range
609.35
| Open | 542.65 | Prev Close | 541.83 | Low | 536.93 | High | 549.66 | Mkt Cap | 23.22B |
| Vol | 407.61K | Avg Vol | 505.80K | EPS | 27.04 | P/E | 20.23 | Forward P/E | 17.05 |
| Beta | 0.57 | Short Ratio | 4.46 | Inst. Own | 102.13% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-29 | 50-d Avg | 560.00 | 200-d Avg | 503.35 | 1yr Est | 665.23 |
UTHR News
marketwatch.com
14 value stocks of companies primed for rapid growth through 2028
Let us begin with a midyear summary of index results that might surprise you in light of the triple-
benzinga.com
FDA Approval Positions United Therapeutics To Broaden Access To Donor Lungs
United Therapeutics received FDA approval for LungFX, a device designed to expand donor lung use in
businesswire.com
United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation